

Access to 2,3-bis(buta-1,3-diyne)pyridines

 Viktor N. Sorokoumov,^a Vladimir V. Popik^b and Irina A. Balova^{*a}
^a Department of Chemistry, St. Petersburg State University, 198504 St. Petersburg, Russian Federation.
Fax: +7 812 428 6939; e-mail: irinabalova@yandex.ru

^b Department of Chemistry, The University of Georgia, Athens, GA 30602, USA

DOI: 10.1016/j.mencom.2011.01.008


Sonogashira cross-coupling of 2-chloro-3-iodopyridines with buta-1,3-diyne gave products of only iodine substitution; in the case of 2-bromo-3-iodopyridine either 2-bromo-3-(buta-1,3-diyne)- or 2,3-bis(buta-1,3-diyne)pyridines were obtained depending on the reaction conditions.

Reversible cyclization of compounds containing a (*Z*)-hex-3-ene-1,5-diyne moiety to form the reactive *p*-benzyne biradical was first reported in 1972 and has become known as the Bergman cyclization.¹ This rather esoteric reaction has attracted a lot of attention in the past two decades when it was found to be the cause of extreme cytotoxicity of natural enediyne antibiotics.² The development of safer and more selective analogues of Neocarzinostatin, Esperamicin, and other natural enediynes is an important goal of the modern medicinal chemistry.^{3,4} Thermal Bergman cycloaromatization of bis-*ortho*-ethynylarenes is also used in preparation of novel materials with unique optical properties.⁵ There is only a single example of such cyclization of enettraynes,⁶ apparently due to the complexity of their preparation. In addition, ‘double’ Bergman cyclization can be considered as a facile access to acenes and heteroacenes, which are of interest as organic electronics, for example, semiconductors including organic thin film transistors⁷ and organic light-emitting diodes.⁸ It is also known that enediynes fused to electron-deficient nitrogen-containing heterocycles, for example, 2,3-diethylpyridine, have a lower activation energy in cycloaromatization compared with carbocyclic enediynes.⁹

We present here the first example of the synthesis of a pyridine-based enettrayne system, 2,3-bis(buta-1,3-diyne)pyridines (Scheme 1). 2-Chloro-3-iodopyridines **3** and 2-bromo-3-iodopyridine **4**, which were prepared from commercially available 2-aminopyridines,¹⁰ were introduced into Pd/Cu-catalyzed Sonogashira cross-coupling¹¹ with two terminal diacetylenes: hexadeca-1,3-diyne **2a** and phenylbuta-1,3-diyne **2b**. Because of low stability of terminal diynes, the synthesis was carried out as one-pot procedure. Hexadeca-1,3-diyne **2a** was obtained by multi-positional prototropic isomerization (‘diacetylene zipper reaction’) of internal isomer hexadeca-7,9-diyne **1a** upon treatment with lithium 2-aminoethylamide (LAETA). This approach was previously successfully used to produce functionalized 1-(het)arylalka-1,3-diyne.¹² 2-Methyl-6-phenylhexa-3,5-diyne-2-ol **1b** served as a synthetic precursor of the diyne **2b** in the *retro*-Favorskii reaction.¹³

The rate of halogen substitution in the cross-coupling reactions is known to decrease in the rank I > Br > Cl. At the same time, halogen atoms at the 2- or 4-positions of pyridine ring are more active in the cross-coupling reactions, as compared to halogen at the 3-position.^{9,14} However, to the best of our knowledge, comparative rates of different halogen atoms substitution in pyridine have not been investigated earlier.

In fact, Sonogashira cross-coupling of 2-chloro-3-iodopyridines **3a,b** with the terminal diyne **2a** using PdCl₂(PPh₃)₂ or



Scheme 1

Pd(PPh₃)₄ catalyst at 65 °C gave only products of iodine substitution, namely, the corresponding 2-chloro-5-methyl-3-(hexa-1,3-diyne)pyridine **5a**[†] and 2-chloro-3,5-bis(hexa-1,3-diyne)pyridine **5b** (Scheme 1). Conducting the reactions at a higher temperature led to the decomposition of unstable terminal diynes.

[†] 2-Chloro-3-(hexa-1,3-diyne)-5-methylpyridine **5a** was obtained from hexadeca-7,9-diyne **1a** and 2-chloro-3-iodo-5-methylpyridine **3a** in 68% yield (for details of the sequence ‘diacetylene zipper’–Sonogashira cross-coupling, see ref. 12). Mp 33–34 °C. IR (CCl₄, ν/cm⁻¹): 3028, 2934, 2912, 2848, 2243, 1854, 1556, 1471, 1407, 1383, 1135, 1065, 902. ¹H NMR (400 MHz, CDCl₃) δ: 0.87 (t, 3H, Me, *J* 7 Hz), 1.26–1.63 [m, 20H, (CH₂)₁₀], 1.29 (s, 3H, Me_{C_{Ar}}), 2.38 (t, 2H, ≡CCH₂, *J* 7 Hz), 7.60 (s, 1H), 8.14 (s, 1H, HC_{Ar}). ¹³C NMR (100 MHz, CDCl₃) δ: 14.1, 17.44, 19.67, 22.67, 28.06, 28.88, 29.06, 29.34, 29.44, 29.58, 29.62, 29.63, 31.90, 64.65, 69.13, 81.27, 87.86, 119.00, 131.70, 142.73, 142.76, 148.85, 150.18. MS, *m/z* (*I*_{rel}, %): 345 [M+2]⁺ (6), 343 [M]⁺ (18), 308 (24), 246 (18), 231 (59), 230 (88), 208 (76), 194 (100), 182 (65), 168 (76), 152 (76), 140 (71), 126 (75), 105 (21). Found (%): C, 76.87; H, 8.78; N, 4.12. Calc. for C₂₂H₃₀ClN (%): C, 76.83; H, 8.79; N, 4.07.

In contrast to **3**, the outcome of the cross-coupling of 2-bromo-3-iodo-5-methylpyridine **4** with terminal diacetylenes depended on the reaction conditions. At 20 °C, the reaction with phenyl-1,3-butadiyne **2b** in the presence of either PdCl₂(PPh₃)₂ or Pd(PPh₃)₄ results in a selective replacement of iodine at the 3-position, with the formation of 2-bromo-5-methyl-3-(4-phenylbuta-1,3-dienyl)pyridine **5c**. Substitution products of both iodine and bromine – 2,3-bis(buta-1,3-dienyl)pyridines **6a,b**[‡] were obtained only in the presence of Pd(PPh₃)₄ at 45 °C. The yields of **6a,b** are lower in comparison with those of **5a–c**, because the increase in temperature led to decomposition of unstable 1,3-dienes.

In conclusion, we showed that the rate of substitution of iodine atoms at the 3- and 5-positions of pyridine ring is significantly higher compared to that of bromine and chlorine atoms at the 2-position in the cross-coupling reactions. This phenomenon gives a possibility for selective introduction of butadiynyl substituents at the 3-position of pyridine ring. In the meanwhile, the use of 2-bromo-3-iodopyridines as the starting material provided access to 2,3-bis(butadiynyl)-substituted pyridine for the first time, the

[‡] *General procedure for 1,3-diyne 2 coupling with 4.* Hexadeca-7,9-diyne **1a** or 2-methyl-6-phenylhexa-3,5-dien-2-ol **1b** (6 mmol) were used for *in situ* 1,3-diyne **2** preparation. When the 'diacetylene zipper'¹² (for obtaining **2a**) or the *retro*-Favorskii reaction¹³ (for obtaining **2b**) was complete, 2-bromo-3-iodopyridine **4** (2 mmol), Pd(PPh₃)₄ (120 mg, 0.1 mmol), PPh₃ (52.5 mg, 0.2 mmol), Et₃N (5 ml) and CuI (57 mg, 0.3 mmol) were added sequentially, in this order to a solution of the 1,3-diyne **2**. The reaction mixture was stirred for a further 8–12 h at 45 °C (TLC control). Upon completion, the reaction mixture was poured into water and the resulting mixture was extracted with diethyl ether (4×25 ml). The combined organic extracts were washed with water and dried over MgSO₄. After solvent evaporation, the product was isolated by flash chromatography on silica gel, eluting with hexane, then hexane–diethyl ether (1:1, v/v) mixtures. 5-Methyl-2,3-bis(4-phenylbuta-1,3-dienyl)pyridine **6b** was obtained in 43% yield (293 mg, 0.86 mmol). ¹H NMR (400 MHz, CDCl₃) δ: 2.54 (s, 3H, Me), 7.32–7.40 (m, 6H), 7.55–7.57 (m, 4H, HC_{ph}), 7.62 (d, 1H, J 1 Hz), 8.39 (d, 1H, HC_{py}, J 1 Hz). ¹³C NMR (100 MHz, CDCl₃) δ: 18.3, 73.7, 73.8, 78.8, 80.3, 83.6, 83.7, 84.0, 84.1, 121.4, 122.2, 122.8, 128.9, 128.5, 128.6, 129.5, 132.6, 132.7, 132.8, 140.3, 141.9, 150.5. MS, *m/z* (*I*_{rel}, %): 342 [M + 1]⁺ (30), 341 [M]⁺ (100), 313 (16), 170 (16), 150 (14).

product being a pyridine enetetrayne derivative. Moreover, selectivity of different halogen reactivity can be further exploited for synthesis of unsymmetrical 2,3-butadiynylpyridines.

This work was supported by the National Science Foundation (grant no. CHE-0449478) and Georgia Cancer Coalition. VS and AB acknowledge also St. Petersburg State University for a research grant.

References

- 1 R. G. Bergman, *Acc. Chem. Res.*, 1973, **6**, 25.
- 2 (a) U. Galm, M. H. Hager, S. G. V. Lanen, J. Ju, J. S. Thorson and B. Shen, *Chem. Rev.*, 2005, **105**, 739; (b) B. Shen and K. Nonaka, *Curr. Med. Chem.*, 2003, **10**, 2317; (c) *Enediyne Antibiotics as Antitumor Agents*, eds. D. B. Borders and T. W. Doyle, Marcel Dekker, New York, 1995; (d) G. B. Jones and F. S. Fouad, *Curr. Pharm. Design*, 2002, **8**, 2415; (e) M. Gredicak and I. Jeric, *Acta Pharm.*, 2007, **57**, 133.
- 3 K. C. Nicolaou and A. L. Smith, in *Modern Acetylene Chemistry*, eds. P. J. Stang and F. Diederich, VCH, Weinheim, 1995, p. 203.
- 4 I. A. Maretina and B. A. Trofimov, *Usp. Khim.*, 2006, **75**, 913 (*Russ. Chem. Rev.*, 2006, **75**, 825).
- 5 C. D. Dimitrakopoulos, S. Purushothaman, J. Kymissis, A. Callegari and J. V. Shaw, *Science*, 1999, **283**, 822.
- 6 I. Ueda, Y. Sakurai, T. Kawano, Y. Wada and M. Futa, *Tetrahedron Lett.*, 1999, **40**, 319.
- 7 A. R. Murphy and J. M. J. Frechet, *Chem. Rev.*, 2007, **107**, 1066.
- 8 J. Anthony, *Chem. Rev.*, 2006, **106**, 5028.
- 9 C. S. Kim and C. Russell, *J. Org. Chem.*, 1998, **63**, 8229.
- 10 (a) E. V. Merkushev, *Usp. Khim.*, 1984, **53**, 583 (*Russ. Chem. Rev.*, 1984, **53**, 343); (b) L. C. Brazdil, J. L. Fitch, C. J. Cutler, D. M. Haynik and E. R. Ace, *J. Chem. Soc., Perkin Trans. 2*, 1998, 933.
- 11 K. Sonogashira, Y. Tohda and N. Hagihara, *Tetrahedron Lett.*, 1975, **16**, 4467.
- 12 I. A. Balova, S. N. Morozkina, V. N. Sorokoumov, O. V. Vinogradova, D. W. Knight and S. F. Vasilevsky, *Eur. J. Org. Chem.*, 2005, 882.
- 13 M. J. Dabdoub, A. C. M. Baroni, J. Leonardão, T. R. Gianeti and G. R. Hurtado, *Tetrahedron*, 2001, **57**, 4371.
- 14 L. Anastasia and E.-i. Negishi, *Chem. Rev.*, 2003, **103**, 1979.

Received: 13th August 2010; Com. 10/3583